NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic and chemotherapeutic agents, today announced that President and Chief Executive Officer, Richard L. Taney, has released the following letter to shareholders:
